Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Feb;73(3):397–399. doi: 10.1038/bjc.1996.68

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

A R Hanauske 1, G Catimel 1, S Aamdal 1, W ten Bokkel Huinink 1, R Paridaens 1, N Pavlidis 1, S B Kaye 1, A te Velde 1, J Wanders 1, J Verweij 1
PMCID: PMC2074418  PMID: 8562349

Abstract

Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose of our studies was to determine the clinical activity of this compound in patients with advanced breast cancer and melanoma. Based on the results of a phase I study, 2.0 mg m-2 was administered as intravenous infusion over 5 min every 21 days. Nineteen patients were entered into the breast cancer phase II trial and received a total of 50 courses (median 2, range 1-6). Of these, dose reductions were performed in three courses because of leucopenia or stomatitis (1.5 mg m-2, one course; 1.45 mg m-2, two courses). Twenty-six patients were entered into the melanoma trial and received a total of 70 courses (median 2, range 1-12). No dose reductions were required. All patients were eligible for toxicity. Haematological toxicity included neutropenia CTC grade 3 (29/120 courses, 24.2%) and grade 4 (11/20 courses, 9.2%). Only drug-related CTC grade 1 thrombocytopenia was observed. Non-haematological toxicity included alopecia in all patients after two courses of treatment as well as CTC grade 3/4 stomatitis and asthenia. In the breast cancer study, one patient achieved a more than 50% tumour reduction after six cycles but was progressing after 6 weeks. Another patient showed a partial remission after the first course but was taken off the study because of CTC grade 3 skin toxicity. One patient was not evaluable for response (early death). No objective remissions were observed in 15 evaluable patients. In melanoma, no objective remissions were observed. We conclude that rhizoxin can be safely administered at 2.0 mg m-2 every 3 weeks. However, it has little activity in patients with advanced breast cancer and melanoma.

Full text

PDF
397

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bai R. L., Pettit G. R., Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem. 1990 Oct 5;265(28):17141–17149. [PubMed] [Google Scholar]
  2. Bissett D., Graham M. A., Setanoians A., Chadwick G. A., Wilson P., Koier I., Henrar R., Schwartsmann G., Cassidy J., Kaye S. B. Phase I and pharmacokinetic study of rhizoxin. Cancer Res. 1992 May 15;52(10):2894–2898. [PubMed] [Google Scholar]
  3. Graham M. A., Bissett D., Setanoians A., Hamilton T., Kerr D. J., Henrar R., Kaye S. B. Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme. J Natl Cancer Inst. 1992 Apr 1;84(7):494–500. doi: 10.1093/jnci/84.7.494. [DOI] [PubMed] [Google Scholar]
  4. Hamel E. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther. 1992;55(1):31–51. doi: 10.1016/0163-7258(92)90028-x. [DOI] [PubMed] [Google Scholar]
  5. Hendriks H. R., Plowman J., Berger D. P., Paull K. D., Fiebig H. H., Fodstad O., Dreef-van der Meulen H. C., Henrar R. E., Pinedo H. M., Schwartsmann G. Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Ann Oncol. 1992 Nov;3(9):755–763. doi: 10.1093/oxfordjournals.annonc.a058334. [DOI] [PubMed] [Google Scholar]
  6. Iwasaki S., Kobayashi H., Furukawa J., Namikoshi M., Okuda S., Sato Z., Matsuda I., Noda T. Studies on macrocyclic lactone antibiotics. VII. Structure of a phytotoxin "rhizoxin" produced by Rhizopus chinensis. J Antibiot (Tokyo) 1984 Apr;37(4):354–362. doi: 10.7164/antibiotics.37.354. [DOI] [PubMed] [Google Scholar]
  7. Iwasaki S., Namikoshi M., Kobayashi H., Furukawa J., Okuda S., Itai A., Kasuya A., Iitaka Y., Sato Z. Studies on macrocyclic lactone antibiotics. VIII. Absolute structures of rhizoxin and a related compound. J Antibiot (Tokyo) 1986 Mar;39(3):424–429. doi: 10.7164/antibiotics.39.424. [DOI] [PubMed] [Google Scholar]
  8. Kerr D. J., Rustin G. J., Kaye S. B., Selby P., Bleehen N. M., Harper P., Brampton M. H. Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer. Br J Cancer. 1995 Nov;72(5):1267–1269. doi: 10.1038/bjc.1995.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kiyoto S., Kawai Y., Kawakita T., Kino E., Okuhara M., Uchida I., Tanaka H., Hashimoto M., Terano H., Kohsaka M. A new antitumor complex, WF-1360, WF-1360A, B, C, D, E and F. J Antibiot (Tokyo) 1986 Jun;39(6):762–772. doi: 10.7164/antibiotics.39.762. [DOI] [PubMed] [Google Scholar]
  10. Otake N. [The structure and antitumor activity of antitumor antibiotics--recent progress]. Gan To Kagaku Ryoho. 1988 Mar;15(3):369–379. [PubMed] [Google Scholar]
  11. Takahashi M., Iwasaki S., Kobayashi H., Okuda S., Murai T., Sato Y., Haraguchi-Hiraoka T., Nagano H. Studies on macrocyclic lactone antibiotics. XI. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues. J Antibiot (Tokyo) 1987 Jan;40(1):66–72. doi: 10.7164/antibiotics.40.66. [DOI] [PubMed] [Google Scholar]
  12. Takahashi M., Iwasaki S., Kobayashi H., Okuda S., Murai T., Sato Y. Rhizoxin binding to tubulin at the maytansine-binding site. Biochim Biophys Acta. 1987 Dec 7;926(3):215–223. doi: 10.1016/0304-4165(87)90206-6. [DOI] [PubMed] [Google Scholar]
  13. Takahashi M., Kobayashi H., Iwasaki S. Rhizoxin resistant mutants with an altered beta-tubulin gene in Aspergillus nidulans. Mol Gen Genet. 1989 Dec;220(1):53–59. doi: 10.1007/BF00260855. [DOI] [PubMed] [Google Scholar]
  14. Takigawa N., Ohnoshi T., Ueoka H., Horiguchi T., Kiura K., Tabata M., Segawa Y., Shibayama T., Genba K., Matsumura T. [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer]. Gan To Kagaku Ryoho. 1993 Jul;20(9):1221–1226. [PubMed] [Google Scholar]
  15. Tsuruo T., Oh-hara T., Iida H., Tsukagoshi S., Sato Z., Matsuda I., Iwasaki S., Okuda S., Shimizu F., Sasagawa K. Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res. 1986 Jan;46(1):381–385. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES